GlassScriptPhysician profile
Jorge G Darcourt
NPI 1811133697
$132,121.00
in general payments reported to CMS, 2019-2025
45 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $489 · 2021: $8,964 · 2022: $16K · 2023: $29K · 2024: $60K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Consulting Fee: $23K · Travel and Lodging: $8,506 · Food and Beverage: $5,098 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,740.00 |
| Consulting Fee | $23,070.00 |
| Travel and Lodging | $8,506.35 |
| Food and Beverage | $5,097.67 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $76,416.52 | 2021-2025 | Trodelvy, Yescarta |
| Lilly USA, LLC | $39,320.61 | 2021-2024 | Verzenio |
| Eli Lilly and Company | $10,898.89 | 2023-2024 | Verzenio |
| Daiichi Sankyo INC. | $1,338.37 | 2022-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $560.94 | 2019-2025 | Xtandi, Xospata |
| Pfizer INC. | $497.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $455.03 | 2022-2025 | |
| Celgene Corporation | $359.27 | 2022-2025 | Reblozyl, Pomalyst, Onureg |
| Janssen Biotech, INC. | $229.71 | 2022-2025 | Rybrevant, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $227.10 | 2023-2025 | Calquence, Enhertu, Imfinzi |
| Genzyme Corporation | $165.80 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $137.29 | 2022-2025 | Opdualag, Opdivo |
| Abbvie INC. | $120.74 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $101.45 | 2022-2025 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $100.95 | 2022 |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Darcourt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.